Borcan Alina Maria, Rotaru Elena, Caravia Laura Georgiana, Filipescu Mihai-Cezar, Simoiu Mădălina
Faculty of Medicine, The University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.
The National Institute of Infectious Diseases "Prof. Dr. Matei Bals", 021205 Bucharest, Romania.
Pharmaceuticals (Basel). 2025 Jun 24;18(7):948. doi: 10.3390/ph18070948.
: Bloodstream infections (BSIs) caused by multidrug-resistant non-fermenting Gram-negative bacilli, particularly and , represent a growing public health concern, especially in tertiary care settings. This study aimed to describe the epidemiological and antimicrobial resistance trends of and isolated from blood cultures over an eight-year period (2017-2024) at a tertiary infectious disease hospital in Bucharest, Romania, especially in the context of the disruption caused by the SARS-CoV-2 pandemic. : A retrospective study was conducted on 43,951 blood cultures processed at the National Institute of Infectious Diseases. Species identification and antibiotic susceptibility testing (AST) were performed using VITEK2, MALDI-TOF MS, and supplementary phenotypic methods. AST interpretation followed EUCAST guidelines. : Out of all of the positive blood cultures, 112 (3.63%) were and 158 (5.12%) . Multidrug-resistance (MDR) was identified in 46% of and 90.73% of isolates. Resistance trends varied, with showing a decrease in MDR rates post-COVID-19 pandemic and following antimicrobial stewardship implementation. In contrast, displayed persistently high resistance, with carbapenem and aminoglycoside resistance rates reaching 100% by 2024. Colistin resistance, though low overall, increased in the latter years. : The findings highlight the dynamic nature of antimicrobial resistance among and . Effective infection control and antimicrobial stewardship programs are crucial in curbing the rise of MDR strains, particularly amid healthcare system disruptions such as the COVID-19 pandemic.
由多重耐药非发酵革兰氏阴性杆菌引起的血流感染（BSIs），尤其是[具体细菌1]和[具体细菌2]，日益引起公众对健康的关注，特别是在三级医疗机构中。本研究旨在描述在罗马尼亚布加勒斯特一家三级传染病医院八年间（2017 - 2024年）从血培养中分离出的[具体细菌1]和[具体细菌2]的流行病学及抗菌药物耐药趋势，特别是在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行造成的干扰背景下。
：对在国家传染病研究所处理的43951份血培养进行了回顾性研究。使用VITEK2、基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）和补充表型方法进行菌种鉴定和抗生素敏感性测试（AST）。AST解释遵循欧洲抗菌药物敏感性试验委员会（EUCAST）指南。
：在所有阳性血培养中，112份（3.63%）为[具体细菌1]，158份（5.12%）为[具体细菌2]。在[具体细菌1]分离株中有46%和[具体细菌2]分离株中有90.73%被鉴定为多重耐药（MDR）。耐药趋势各不相同，[具体细菌1]显示在2019冠状病毒病大流行后及实施抗菌药物管理措施后多重耐药率有所下降。相比之下，[具体细菌2]表现出持续的高耐药性，到2024年碳青霉烯类和氨基糖苷类耐药率达到100%。黏菌素耐药性虽然总体较低，但在后期有所增加。
：研究结果突出了[具体细菌1]和[具体细菌2]中抗菌药物耐药性的动态性质。有效的感染控制和抗菌药物管理计划对于遏制多重耐药菌株的增加至关重要，特别是在诸如2019冠状病毒病大流行等医疗系统中断期间。
